In this study, we aimed to measure the longitudinal changes in CSF sTREM2 level in the A/T/N classification system for AD biomarkers and determine the possible association with AD pathological hallmarks including Aβ plaques and tau aggregates. The gene discussed is MAPT; the disease is Alzheimer disease.